Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing compound containing saccharide radical
Reexamination Certificate
1998-04-17
2001-03-27
Horlick, Kenneth R. (Department: 1656)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing compound containing saccharide radical
C435S006120, C435S091200, C435S069100, C536S023100, C536S023400, C536S023500, C536S024300, C536S024310, C536S024330
Reexamination Certificate
active
06207422
ABSTRACT:
BACKGROUND OF THE INVENTION
The electrical properties of excitable cells are determined in large part by the voltage-gated K
+
channels, i.e., “Kv channels”, present on the plasma membrane of such cells. Kv channels are also important in many nonexcitable cells where they contribute to diverse processes such as volume regulation, hormone secretion, and activation by mitogens. At least 50 different Kv channel genes have been identified, and most have been assigned to one of the following four major subfamilies: Kv1, Kv2, Kv3, and Kv4. Each Kv channel gene encodes a single pore-forming subunit, referred to as the &agr;-subunit. Functional Kv channels are formed by the tetrameric association of individual &agr;-subunits. With multiple Kv&agr; proteins that assemble as multi-subunit heteromeric complexes, there may be hundreds of functionally distinct Kv channels.
Kv channels, either functioning or malfunctioning, are implicated in many disease states including cardiac arrhythmias, hypertension, angina, asthma, diabetes, renal insufficiency, urinary incontinence, irritable colon, epilepsy, cerebrovascular ischemia and autoimmune diseases Accordingly, efforts are underway to identify and characterize pharmacological agents that alter the kinetics, gating or formation of Kv channels. The efficacy of such agents is determined by treating cells with such agents and measuring changes in current across the plasma membrane of the cells. Unfortunately, it is difficult to measure small changes in the current in most cells. It is also difficult to determine whether a pharmocological agent alters current flow through a specific Kv channel. Accordingly, it is desirable to have methods and tools which can be used to regulate the numbers and types of Kv channels on the plasma membrane of cells. It is also desirable to have new research tools that can be used for examining the assembly and synthesis of Kv channels.
SUMMARY OF THE INVENTION
The present invention provides novel polynucleotides that encode a novel protein, designated herein as K+ Channel Associated Protein or “KChAP”. It has been determined that expressing polynucleotides that encode KCHAP in host cells, along with polynucleotides that encode the Kvo channel subunit Kv 2.1, the Kv&agr; channel subunit Kv 2.2, the Kvc channel subunit Kv 1.3, or the Kv&agr; channel subunit Kv 4.3, increases the number of Kv2.1, Kv 2.2, Kv1.3 or Kv4.3 channels, respectively, in the plasma membrane of such cells. Accordingly, KChAP polynucleotides are useful for making cells that have increased numbers of Kv channels on the cellular plasma membrane. Such cells are useful model systems for studying the effect of pharmacological agents on Kv channels, particularly on Kv2.1, Kv 2.2, Kv 1.3, and Kv 4.3 channels.
The present invention also relates to the novel protein KChAP. During formation of Kv channels, KChAP binds to the Kvx channel subunits Kv2. 1, Kv2.2, Kv1.3, and Kv4.3 within the cytoplasm of the cell. KChAP also binds to the Kv&agr; channel subunits Kv1.2, Kv 1.4, Kv1.5 and Kv 3.1 and to Kvp subunits. Accordingly, KChAP and the antibodies that are immunospecific for KChAP are useful research tools for monitoring the interaction between diverse Kvx channel subunits and KCHAP and for monitoring the interaction between Kv&agr; subunits and Kv&agr; subunits.
REFERENCES:
patent: 5492825 (1996-02-01), Jan et al.
patent: 5670335 (1997-09-01), Jan et al.
patent: 5756669 (1998-05-01), Bishcoff et al.
patent: 5856449 (1999-01-01), Groppi, Jr. et al.
patent: 5882873 (1999-03-01), Bienkowski et al.
patent: WO9531544 (1995-11-01), None
“Cloning and Characterization of Gu/RH-II Binding Protein” by Valdez, et al.,Biochemical and Biophysical Research Communications, 234, 1997, pp. 335-340.
“Specific Inhibition of Stat3 Signal Transduction by PIAS3” by Chung, et al.,Science, vol. 278, Dec., 1997, pp. 1803-1805.
“Mizl, a novel zinc finger transcription factor that interacts with Msx2 and enhances its affinity for DNA” by Wu, et al.,Mechanisms of Development65, 1997, pp. 3-17.
“Cloning and Expression of a Novel K+ Channel Regulatory Protein, KChAP”, Wible, et al.,Journal of Biological Chemistry, vol. 273, No. 19, May 8, 1998, pp. 11745-11751.
Brown Arthur M.
Wible Barbara A.
Yang Qing
Calfee Halter & Griswold LLP
Horlick Kenneth R.
Siew Jeffrey
The MetroHealth System
LandOfFree
Protein that enhances expression of potassium channels on... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein that enhances expression of potassium channels on..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein that enhances expression of potassium channels on... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2515467